Literature DB >> 26358609

Draft Genome Sequence of a vanA-Type Vancomycin-Resistant Reference Strain, Enterococcus faecium ATCC 51559.

Kidon Sung1, Saeed Khan2, Bernard Marasa2, Seonggi Min3, Ohgew Kweon2, Nawaz Mohamed2, Carl Cerniglia2.   

Abstract

Vancomycin-resistant Enterococcus faecium has emerged as a multidrug-resistant pathogen in hospital settings. Here, we present the draft genome sequence of a high-level vancomycin-resistant strain, E. faecium ATCC 51559, which is employed as a standard laboratory vanA genotype-positive control strain for clinical and laboratory studies.
Copyright © 2015 Sung et al.

Entities:  

Year:  2015        PMID: 26358609      PMCID: PMC4566191          DOI: 10.1128/genomeA.01053-15

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Vancomycin-resistant enterococci (VRE) cause one-third of the most common bloodstream infections among hospitalized patients (1, 2). VRE isolates that exhibit a high level of resistance to vancomycin carry the vanA gene, which is present on a 10.8-kb transposon, Tn1546 (3). This mobile genetic element can transfer to other pathogenic microorganisms and make them resistant to vancomycin. Since vancomycin is considered one of the last-resort antibiotics to treat infections caused by Gram-positive bacteria, management of VRE infections becomes difficult. Accurate and prompt detection of the antimicrobial susceptibility profiles of VREs is therefore necessary to prevent and control nosocomial outbreaks, allowing patients to be administered appropriate drugs. Several studies of the composition of plating/broth medium and growth conditions have been conducted to validate accuracy of (4, 5) and influence on antibiotic susceptibility profiles of VREs (6, 7). The effect of plating medium, however, was not correlated with the presence of vancomycin resistance genes in these studies. E. faecium ATCC 51599, a clinical isolate that was isolated from a patient in Brooklyn, New York, is used as a quality control strain for antimicrobial susceptibility testing (8). It contains the vanA gene on transposon Tn1546, which is quite prone to mutations and proved very helpful in understanding the phenomenon of vancomycin heteroresistance in different growth media (9, 10). The genomic DNA of E. faecium 51599 was extracted using a Master Pure Gram-positive DNA purification kit (Epicentre Biotechnologies). A TruSeq DNA library preparation kit (Illumina) and TruSeq paired-end cluster kit were used for the DNA preparation and cluster generation for sequencing on a HiSeq system, respectively. An Illumina HiSeq 2500 system was used for sequencing. De novo assembly of a total of 37,959,664 high-quality paired-end reads (100 bp in length) was conducted using the CLC genomics workbench 6.5.1 (CLC Bio), and further genome annotation was performed using an annotation method GeneMarkS+ in the NCBI Prokaryotic Genome Annotation Pipeline (http://www.ncbi.nlm.nih.gov/genomes/static/Pipeline.html). The draft genome sequence of E. faecium 51599 was 2,953,574 bp in length with a G+C content of 37.7%, which is distributed in 160 contigs (N50 length, 52,737; average coverage, 2155.0×) with 2,831 coding sequences (CDS) and 56 RNAs.

Nucleotide sequence accession numbers.

This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession number JSVT00000000. The version described in this paper is version JSVT00000000.1.
  10 in total

1.  Heteroresistance to vancomycin and novel point mutations in Tn1546 of Enterococcus faecium ATCC 51559.

Authors:  Saeed A Khan; Kidon Sung; Sherryll Layton; Mohamed S Nawaz
Journal:  Int J Antimicrob Agents       Date:  2007-10-23       Impact factor: 5.283

2.  Comparison of eight methods to detect vancomycin resistance in enterococci.

Authors:  H P Endtz; N Van Den Braak; A Van Belkum; W H Goessens; D Kreft; A B Stroebel; H A Verbrugh
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin.

Authors:  D Landman; N K Mobarakai; J M Quale
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

4.  Comparison of agar dilution, broth microdilution, E-test, disk diffusion, and automated Vitek methods for testing susceptibilities of Enterococcus spp. to vancomycin.

Authors:  P C Kohner; R Patel; J R Uhl; K M Garin; M K Hopkins; L T Wegener; F R Cockerill
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

Review 5.  Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications.

Authors:  L C McDonald; M J Kuehnert; F C Tenover; W R Jarvis
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

6.  Nosocomial enterococci resistant to vancomycin--United States, 1989-1993.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1993-08-06       Impact factor: 17.586

7.  Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147.

Authors:  M Arthur; C Molinas; F Depardieu; P Courvalin
Journal:  J Bacteriol       Date:  1993-01       Impact factor: 3.490

8.  Influence of growth media on vancomycin resistance of Enterococcus isolates and correlation with resistance gene determinants.

Authors:  Rajesh Nayak; Saeed A Khan; Robert H Watson; Carl E Cerniglia
Journal:  FEMS Microbiol Lett       Date:  2002-09-10       Impact factor: 2.742

9.  Effects of different test conditions on MICs of food animal growth-promoting antibacterial agents for enterococci.

Authors:  P Butaye; L A Devriese; F Haesebrouck
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

10.  Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis.

Authors:  D F Sahm; C Torres
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.